Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703 von Schmidt, Manuel, Hagner, Nicole, Marco, Alberto, König-Merediz, Sven A., Schroff, Matthias, Wittig, Burghardt

Volltext

Genuine Immunomodulation With dSLIM von Kapp, Kerstin, Kleuss, Christiane, Schroff, Matthias, Wittig, Burghardt

Volltext

Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein va... von Endmann, Anne, Klünder, Katharina, Kapp, Kerstin, Riede, Oliver, Oswald, Detlef, Talman, Eduard G, Schroff, Matthias, Kleuss, Christiane, Ruiters, Marcel H J, Juhls, Christiane

Volltext

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist von Volz, Barbara, Schmidt, Manuel, Heinrich, Kerstin, Kapp, Kerstin, Schroff, Matthias, Wittig, Burghardt

Volltext

Cavrotolimod, a Nanoparticle Toll-like Receptor 9 Agonist, Inhibits Tumor Growth and Alters Immune Cell Composition in Mouse Models of Skin Cancer von Mix, Scott, Schroff, Matthias, Daniel, Weston L.

Volltext

Peripheral Non-Viral MIDGE Vector-Driven Delivery of β-Endorphin in Inflammatory Pain von Machelska, Halina, Schroff, Matthias, Oswald, Detlef, Binder, Waltraud, Sitte, Nicolle, Mousa, Shaaban A, Rittner, Heike L, Brack, Alexander, Labuz, Dominika, Busch, Melanie, Wittig, Burghardt, Schäfer, Michael, Stein, Christoph

Volltext

A Novel Minimal-Size Vector (MIDGE) Improves Transgene Expression in Colon Carcinoma Cells and Avoids Transfection of Undesired DNA von Schakowski, F, Gorschlüter, M, Junghans, C, Schroff, M, Buttgereit, P, Ziske, C, Schöttker, B, König-Merediz, S A, Sauerbruch, T, Wittig, B, Schmidt-Wolf, I G

Volltext

Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or w... von Leutenegger, C M, Boretti, F S, Mislin, C N, Flynn, J N, Schroff, M, Habel, A, Junghans, C, Koenig-Merediz, S A, Sigrist, B, Aubert, A, Pedersen, N C, Wittig, B, Lutz, H

Volltext

740. The TLR9 Agonist EnanDIM® - Evaluation of New Enantiomeric Oligonucleotides for Cancer Immunotherapy In Vitro and In Vivo von Kapp, Kerstin, Schroff, Matthias, Wittig, Burghardt, Schmidt, Manuel

Volltext

Minimal Size MIDGE Vectors Improve Transgene Expression In Vivo von FRANK SCHAKOWSKI, MARCUS GORSCHLÜTER, PETER BUTTGEREIT, ANGELA MÄRTEN, MARIE V. LILIENFELD-TOAL, CLAAS JUNGHANS, MATTHIAS SCHROFF, SVEN A. KÖNIG-MEREDIZ, CARSTEN ZISKE, JOHN STREHL, TILMAN SAUERBRUCH, BURGHARDT WITTIG, INGO G.H. SCHMIDT-WOLF

Volltext

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours von Weihrauch, Martin R, Richly, Heike, von Bergwelt-Baildon, Michael S, Becker, Hans Jiro, Schmidt, Manuel, Hacker, Ulrich T, Shimabukuro-Vornhagen, Alexander, Holtick, Udo, Nokay, Bahar, Schroff, Matthias, Wittig, Burghardt, Scheulen, Max E

Volltext

Abstract 2565: Conformation overrides base sequence - insights from a novel class TLR-9 agonists von Kapp, Kerstin, Kleuss, Christiane, Schroff, Matthias, Wittig, Burghardt

Volltext

Pharmacokinetic and pharmacodynamic data of the immunotherapeutic TLR-9 agonist MGN1703 from healthy volunteers and cancer patients von Schmidt, Manuel, Kapp, Kerstin, Oswald, Detlef, Schroff, Matthias, Wittig, Burghardt, Zurlo, Alfredo

Volltext

Abstract 4558: Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m von Wieckowski, Sébastien, Podola, Lilli, Springer, Marco, Kobl, Iris, Koob, Zina, Mignard, Caroline, Berkane, Amine Adda, Wei, Ming, Meichle, Albrecht, Breiner, Klaus, Schroff, Matthias, Beckhove, Philipp, Lubenau, Heinz

Volltext

MGN1703 - structure of agonist determines cellular responses to TLR9 activation von Kapp, Kerstin, Kleuss, Christiane, Schmidt, Manuel, Schroff, Matthias, Wittig, Burghardt

Volltext

ITOC2 – 035. The immunotherapeutic TLR-9 agonist MGN1703 – Pharmacokinetic and pharmacodynamic data from healthy volunteers and cancer patients von Manuel, Schmidt, Kerstin, Kapp, Detlef, Oswald, Matthias, Schroff, Burghardt, Wittig, Alfredo, Zurlo

Volltext

213. Treatment with MGN1601 Induces Immune Responses Against Tumor Associated Antigens in Patients with Renal Cell Carcinoma von Schmidt, Manuel, Volz, Barbara, Kapp, Kerstin, Grünwald, Viktor, Schroff, Matthias, Wittig, Burghardt

Volltext

Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1 von Wieckowski, Sébastien, Smetak, Heiko, Kobl, Iris, Podola, Lilli, Nugues, Anne-Lucie, Slos, Philippe, Adda Berkane, Amine, Wei, Ming, Breiner, Klaus M., Meichle, Albrecht, Mansour, Marc, Schroff, Matthias, Beckhove, Philipp, Lubenau, Heinz

Volltext

Abstract B196: Live attenuated oral Salmonella platform for effective targeting of multiple tumor-associated epitopes and PD-L1 von Wieckowski, Sébastien, Podola, Lilli, Springer, Marco, Kobl, Iris, Smetak, Heiko, Nugues, Anne-Lucie, Slos, Philippe, Adda Berkane, Amine, Wei, Ming, Breiner, Klaus, Meichle, Albrecht, Philipp, Beckhove, Mansour, Marc, Schroff, Matthias, Lubenau, Heinz

Volltext

Immune response induced by a linear DNA vector: Influence of dose, formulation and route of injection von Endmann, Anne, Baden, Michael, Weisermann, Elena, Kapp, Kerstin, Schroff, Matthias, Kleuss, Christiane, Wittig, Burghardt, Juhls, Christiane

Volltext